NASDAQ:GTXI - GTX Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.23 -0.05 (-3.91 %)
(As of 12/10/2018 04:00 PM ET)
Previous Close$1.28
Today's Range$1.22 - $1.29
52-Week Range$1.22 - $25.60
Volume234,122 shs
Average Volume724,612 shs
Market Capitalization$30.79 million
P/E Ratio-0.70
Dividend YieldN/A
Beta1.6
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer. The company's lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Receive GTXI News and Ratings via Email

Sign-up to receive the latest news and ratings for GTXI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GTXI
Previous Symbol
CUSIP40052B10
Phone901-523-9700

Debt

Debt-to-Equity RatioN/A
Current Ratio4.32
Quick Ratio4.32

Price-To-Earnings

Trailing P/E Ratio-0.70
Forward P/E Ratio-0.75
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.78 per share
Price / Book0.69

Profitability

EPS (Most Recent Fiscal Year)($1.75)
Net Income$-30,430,000.00
Net MarginsN/A
Return on Equity-126.41%
Return on Assets-100.34%

Miscellaneous

Employees27
Outstanding Shares24,050,000
Market Cap$30.79 million
OptionableOptionable

GTX (NASDAQ:GTXI) Frequently Asked Questions

What is GTX's stock symbol?

GTX trades on the NASDAQ under the ticker symbol "GTXI."

How were GTX's earnings last quarter?

GTx, Inc. (NASDAQ:GTXI) announced its quarterly earnings results on Thursday, November, 15th. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing analysts' consensus estimates of ($0.30) by $0.09. View GTX's Earnings History.

When is GTX's next earnings date?

GTX is scheduled to release their next quarterly earnings announcement on Monday, March 11th 2019. View Earnings Estimates for GTX.

What price target have analysts set for GTXI?

2 Wall Street analysts have issued twelve-month target prices for GTX's stock. Their predictions range from $17.00 to $45.00. On average, they expect GTX's share price to reach $31.00 in the next year. This suggests a possible upside of 2,420.3% from the stock's current price. View Analyst Price Targets for GTX.

What is the consensus analysts' recommendation for GTX?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GTX in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GTX.

Has GTX been receiving favorable news coverage?

News stories about GTXI stock have been trending somewhat positive on Monday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. GTX earned a daily sentiment score of 1.9 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent news coverage is likely to have an impact on the company's share price in the next several days.

Are investors shorting GTX?

GTX saw a decline in short interest in the month of October. As of October 31st, there was short interest totalling 2,663,051 shares, a decline of 33.2% from the October 15th total of 3,988,103 shares. Based on an average daily volume of 1,353,850 shares, the days-to-cover ratio is currently 2.0 days. Approximately 31.2% of the shares of the stock are sold short. View GTX's Current Options Chain.

Who are some of GTX's key competitors?

Who are GTX's key executives?

GTX's management team includes the folowing people:
  • Dr. Robert James Wills Ph.D., Exec. Chairman (Age 64)
  • Mr. Marc S. Hanover, Co-Founder, CEO & Director (Age 55)
  • Mr. Henry P. Doggrell, VP, Chief Legal Officer & Sec. (Age 69)
  • Mr. Jason T. Shackelford, VP of Fin. & Accounting, Principal Financial & Accounting Officer and Corp. Controller (Age 43)
  • Dr. Diane C. Young, VP & Chief Medical Officer (Age 61)

Who are GTX's major shareholders?

GTX's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.00%), Vanguard Group Inc. (1.94%), Bridgeway Capital Management Inc. (1.14%), Candriam Luxembourg S.C.A. (1.09%) and Vivo Capital LLC (0.44%). Company insiders that own GTX stock include Diane C Young, Henry Patton Doggrell, Jason T Shackelford, Marc Steven Hanover and Robert James Wills. View Institutional Ownership Trends for GTX.

Which major investors are buying GTX stock?

GTXI stock was purchased by a variety of institutional investors in the last quarter, including Bridgeway Capital Management Inc., Candriam Luxembourg S.C.A., Vivo Capital LLC, BlackRock Inc. and Vanguard Group Inc.. View Insider Buying and Selling for GTX.

How do I buy shares of GTX?

Shares of GTXI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GTX's stock price today?

One share of GTXI stock can currently be purchased for approximately $1.23.

How big of a company is GTX?

GTX has a market capitalization of $30.79 million. The biopharmaceutical company earns $-30,430,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. GTX employs 27 workers across the globe.

What is GTX's official website?

The official website for GTX is http://www.gtxinc.com.

How can I contact GTX?

GTX's mailing address is 175 TOYOTA PLAZA 7TH FLOOR, MEMPHIS TN, 38103. The biopharmaceutical company can be reached via phone at 901-523-9700 or via email at [email protected]


MarketBeat Community Rating for GTX (NASDAQ GTXI)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  170 (Vote Underperform)
Total Votes:  360
MarketBeat's community ratings are surveys of what our community members think about GTX and other stocks. Vote "Outperform" if you believe GTXI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GTXI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel